公开(公告)号：US20150023989A1

公开(公告)日：2015-01-22

申请号：US14364203

申请日：2012-12-12

申请人： SEATTLE GENETICS, INC.

发明人： Hans-Georg Lerchen ,  Stefanie Hammer ,  Axel Harrenga ,  Charlotte Christine Kopitz ,  Carl Friedrich Nising ,  Anette Sommer ,  Beatrix Stelte-Luowig ,  Christoph Mahlert ,  Joachim Schuhmacher ,  Sven Golfier ,  Simone Greven ,  Sandra Bruder

IPC分类号： A61K47/48 ,  A61K38/05

CPC分类号： A61K38/05 ,  A61K47/6849

摘要： The present application relates to new antibody drug conjugates (ADCs) of N,N dialkylauristatins directed against the target FGFR2, drug metabolites of said ADCs, a method for producing said ADCs, the use of said ADCs for the treatment and/or prevention of illnesses as well as the use of said ADCs for producing pharmaceuticals for the treatment and/or prevention of illnesses, particularly of hyperproliferative and/or angiogenic diseases such as carcinosis. Such treatments can be carried out as monotherapy or in combination with other pharmaceuticals or additional therapeutic measures.

摘要翻译： 本申请涉及针对靶FGFR2的N，N二烷基硫酸钠的新抗体药物共轭物（ADC），所述ADC的药物代谢物，所述ADC的制备方法，所述ADC用于治疗和/或预防疾病 以及使用所述ADC用于生产用于治疗和/或预防疾病，特别是过度增生和/或血管生成疾病如癌症的药物。 这样的治疗可以作为单一疗法或与其它药物或其它治疗措施结合进行。